On the morning of February 20, People Digital Anhui learned from a press conference held by the Office of the Leading Group for Epidemic Prevention and Control of Anhui Province that the new coronavirus vaccine developed by Anhui Zhifeilongkema Biopharmaceutical Co., Ltd. has been included in the Ministry of Science and Technology "Public Safety "Risk prevention and control and emergency technical equipment" key special project. Currently, vaccine development is in the pre-clinical research stage. It is reported that the design of the vaccine has been completed, and the immunity effect in animals is being verified. At the same time, production process research and development, production workshop transformation, and quality assurance system construction are also being carried out simultaneously.
According to Pu Jiang, general manager of Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd., after the outbreak, the company used its accumulation and advantages in the field of vaccine research and development for more than ten years to start research and development of new coronavirus vaccines. Currently, the company is the only company in Anhui Province that develops a new coronavirus vaccine.
It is understood that of the company's 532 employees who are currently returning to work, hundreds of them have invested in the research and development of the new coronavirus vaccine. At the same time, the company also mobilized other R&D forces of Zhifei Biological Group to participate in the research and development of the vaccine.
"We use recombinant gene technology to prepare subunit vaccines, which have the advantages of higher safety, better stability, strong immunogenicity, long-lasting immunity, and rapid realization of large-scale production." Pu Jiang said that the new coronavirus vaccine is innovative For vaccines, the risks of vaccines must be fully evaluated. The company will go all out to overcome difficulties and strive to get the vaccine approved for marketing as soon as possible while ensuring that the vaccine is safe and effective. (Text/Zhang Congjun Picture/Liu Weixin)
